The document discusses the in vitro dissolution profiles of two extended-release formulations of propranolol hydrochloride tablets, labeled ERF and ERS, that are designed to have different release rates.
The document discusses the in vitro dissolution profiles of two extended-release formulations of propranolol hydrochloride tablets, labeled ERF and ERS, that are designed to have different release rates.
The document discusses the in vitro dissolution profiles of two extended-release formulations of propranolol hydrochloride tablets, labeled ERF and ERS, that are designed to have different release rates.